Julie Schwartzman Morris, MD
Rheumatology · Great Neck, NYNPI 1518919463
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $350 of the $436 with a category attached, or 80.2%. AstraZeneca accounts for 80.2% of it on its own, with 1 other manufacturer making up the rest. That places this record below the midpoint for rheumatology clinicians in NY, where the typical reported total is $1,764.
Across 2 payments — averaging $218.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$350
- Abbott$86
Across 2 payments — averaging $4871.30 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$9K
- Novartis$1K
What the payments were for
- Consulting fees$35080%
- Food & beverage$8620%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 1 | $350 |
| Abbott | 1 | $86 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ULTOMIRIS$350
How this compares
$436 in reported general payments places this provider in the 35th percentile of 541 rheumatology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Taltz AutoinjectorIxekizumab | 27 | $175,506 |
| TremfyaGuselkumab | 11 | $147,414 |
| Xeljanz XrTofacitinib Citrate | 17 | $96,739 |
| Cimzia (2 Pack)Certolizumab Pegol | 11 | $64,741 |
| OtrexupMethotrexate/Pf | 18 | $13,133 |
| RasuvoMethotrexate/Pf | 13 | $6,892 |
| Mycophenolate Mofetil | 14 | $2,368 |
| Hydroxychloroquine Sulfate | 63 | $2,121 |
| Duloxetine Hcl | 38 | $2,107 |
| MethotrexateMethotrexate Sodium | 97 | $1,500 |
| Allopurinol | 41 | $1,333 |
| Ibandronate Sodium | 18 | $639 |
| Gabapentin | 30 | $524 |
| Diclofenac Sodium | 14 | $411 |
| Amitriptyline Hcl | 14 | $399 |
Paid to pharmacies, not to this prescriber.
Other rheumatology in Great Neck
- Sonali NarainGreat Neck$54K
- Laurie GlimcherNew York$3.9M
- Grace WrightNew York$3M
- Kostas BotsoglouCheektowaga$2.6M
- Sergio SchwartzmanNew York$2.5M
- Allan GibofskyNew York$1.9M
- Petros EfthimiouNew York$791K
- Richard FurieNew Hyde Park$746K
- Barry GruberBabylon$742K
- Olga PetrynaNew York$509K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.